New treatment target verification for myelodysplastic syndrome

A Japanese research group analyzed the pathophysiology of myelodysplastic syndrome (MDS), a blood cancer that presents often in the elderly, and found the presence of transcription factor RUNX3, thereby revealing a cancer growth function for what had been considered be a tumor suppressor. Additional analyses of human MDS cells and model mice found an abnormal gene expression mechanism linked to the onset of cancer, and confirmed RUNX3 as a potential therapeutic target.